Study of anti-inflammatory activity and acute toxicity indicators of new silver salt of pyrazole-3-carboxamide

Abstract

Objective. To study the anti-inflammatory activity and some toxicological indicators of the new derivative of pyrazole-3-carboxamide SSP.

Materials and methods. To assess the biological activity of the compound, its anti-inflammatory effect was studied in the model of acute inflammatory edema caused by sub-plantar injection of carrageenan solution into a rat`s hind leg. The duration effect was assessed by the intensity of suppression of the inflammatory response in relation to the control level. In order to study the safety of the substance, the local irritant effect was determined when applied cutaneously in the experiments on rats. The severity of the irritant effect was assessed by the erythema degree, the amount of edema and the increase in local skin temperature. In addition, acute toxicity of the substance under study was determined. The test compound and reference drugs were applied to the skin.

Results. The study of acute toxicity of the compound SSP and the reference drug nystatin when applied cutaneously to rats showed that LD₅₀ of both substances was more than 2500,0 mg/kg. Indicators of the degree of local irritating effect of the drugs demonstrate its absence. At the same time, the studied SSP compound has no anti-inflammatory effect administered either orally or cutaneously.

Conclusions. The data obtained allow us to classify the new silver salt of pyrazol-3-carboxamide SSP as a class 5 non-toxic substance. The studied SSP compound has no local irritant effect and does not demonstrate anti-inflammatory activity in the carrageenan inflammation model.

Keywords

Silver salt of pyrazol-3-carboxamide / acute toxicity / carrageenan inflammation model / local irritant effect / nystatin / nimesulide

References

[1] Новикова В.В., Кучевасова М.В. Эпидемиологические особенности микозов волосистой части головы в Пермском крае. Сибирское медицинское обозрение 2023; 1 (143): 46–51 / Novikova V.V., Kuchevasova M.V. Epidemiologicheskie osobennosti mikozov volosistoj chasti golovy v Permskom krae. Sibirskoe medicinskoe obozrenie 2023; 1 (143): 46–51 (in Russian).

[2] Белоусова Т.А., Каиль-Горячкина М.В. Дерматофитии стоп: проблемы коморбидности и персонализированный выбор терапии. Consilium Medicum. Дерматология (Прил.) 2019; 1: 27–31 / Belousova T.A., Kail'-Goryachkina M.V. Dermatofitii stop: problemy komorbidnosti i personalizirovannyj vybor terapii. Consilium Medicum. Dermatologiya (Pril.) 2019; 1: 27–31 (in Russian).

[3] Pal M., Dave P., Dave K., Gutama K.P., Thangavely L., Paula C.R. et al. Etiology, clinical spectrum, epidemiology, new developments in diagnosis and therapeutic management of onychomycosis: an update. Am. J. Microbiol. Res. 2023; 11 (1): 19–24.

[4] Набиева Д.Д., Абдуллаев М.И. Кожные проявления и клинико-лабораторные особенности у ВИЧ-инфицированных детей. Original medicine 2023; 1: 77–84 / Nabieva D.D., Abdullaev M.I. Kozhnye proyavleniya i kliniko-laboratornye osobennosti u VICH-inficirovannyh detej. Original medicine 2023; 1: 77–84 (in Russian).

[5] Егорова Е.А., Шейхмамбетова Л.Р., Бекирова Э.Ю. Маркетинговый анализ ассортимента противогрибковых препаратов для местного применения на фармацевтическом рынке Российской Федерации. Современная организация лекарственного обеспечения 2021; 8 (1): 7–13 / Egorova E.A., Shejhmambetova L.R., Bekirova E.Yu. Marketingovyj analiz assortimenta protivogribkovyh preparatov dlya mestnogo primeneniya na farmacevticheskom rynke Rossijskoj Federacii. Sovremennaya organizaciya lekarstvennogo obespecheniya 2021; 8 (1): 7–13 (in Russian).

[6] Новикова В.В., Бобровская О.В., Гейн В.Л. Противогрибковая активность серебряных солей пирроло[3,4-с] пиразол-3-онов и пиразол-3-карбоксамидов, содержащих сульфамидную группу. Химико-фармацевтический журнал 2023; 57 (8): 41–45 / Novikova V.V., Bobrovskaya O.V., Gejn V.L. Protivogribkovaya aktivnost' serebryanyh solej pirrolo[3,4-s] pirazol-3-onov i pirazol-3-karboksamidov, soderzhashchih sul'famidnuyu gruppu. Himiko-farmacevticheskij zhurnal 2023; 57 (8): 41–45 (in Russian).

[7] Руководство по проведению доклинических исследований лекарственных средств. Под ред. А.Н. Миронова. М.: Гриф и К 2012; 944 / Guidelines for conducting preclinical studies of medicinal products. Pod red. A.N. Mironova. Moscow: Grif i K 2012; 944 (in Russian).

[8] Прозоровский В.Б. Статистическая обработка результатов фармакологических исследований. Психофармакология и биологическая наркология 2007; 3–4: 2090–2120 / Prozorovskiy V.B. Statistical processing of the results of pharmacological studies. Psikhofarmakologiya i biologicheskaya narkologiya 2007; 3–4: 2090–2120 (in Russian).

Funding

Правительство РФGovernment of RF(720000Ф.99.1.БН62АБ05000)

RIGHTS & PERMISSIONS

Eco-Vector